This pricing supplement, which is not complete and may be changed, relates to an effective Registration Statement under the Securities Act of 1933. This pricing supplement and the accompanying product supplement, prospectus supplement and prospectus are not an offer to sell these Notes in any country or jurisdiction where such an offer would not be permitted.
BofA Finance LLC $--
... (continue reading...)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-D
ASSET-BACKED ISSUER DISTRIBUTION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the monthly distribution period from
August 1, 2026 to August 31, 2026
Commission File Number of Issuing Entity: 333-251538-01
Central Index Key Number of Issuing Entity: 0001833494
WF CARD ISSUANCE TRUST
(Exact name of issuing entity as... (continue reading...)
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-42710
Sol Strategies Inc.(Translation of registrant's name into English)
217 Queen Street West, Suite 401Toronto, Ontario, M5V 0R2, Canada(Address of principal executive offices)
Indicate... (continue reading...)
The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, prospectus supplement and prospectus are not an offer to sell these securities, nor are they soliciting an offer to buy these securities, in any state where the... (continue reading...)
More SEC Filings
View Older Stories-
Form 424B3 Biodexa Pharmaceuticals
-
Form 424B3 Biodexa Pharmaceuticals
-
Form 424B3 Biodexa Pharmaceuticals
-
Form 424B3 Biodexa Pharmaceuticals
-
Form 424B3 Biodexa Pharmaceuticals
-
Form 424B3 Biodexa Pharmaceuticals
-
Form 424B3 Biodexa Pharmaceuticals
-
Form 8-K SCOTTS MIRACLE-GRO CO For: Sep 15
-
Form 424B5 nVent Electric plc
-
Form 4 Lincoln International, For: Sep 15 Filed by: Oleniczak John William
-
Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 15
-
Form 424B2 CITIGROUP INC
-
Form D/A White Oaks Low Volatilit
-
Form 8-K Scholar Rock Holding For: Sep 15
-
Form 8-K Evommune, Inc. For: Sep 15
-
Form 3 Bowhead Specialty Holdin For: Sep 12 Filed by: Walker Derek Z
-
Form 6-K SaverOne 2014 Ltd. For: Sep 15
-
Form 6-K Biodexa Pharmaceuticals For: Sep 15
-
Form D/A White Oaks Alternative
-
Form 424B3 LB PHARMACEUTICALS INC
-
Form 8-K USA TODAY Co., Inc. For: Sep 15
-
Form 8-K AGNT, Inc. For: Sep 14
-
Form 3 Resolution Minerals Ltd For: Sep 09 Filed by: Lindsay Craig Thomas
-
Form 8-K AETHLON MEDICAL INC For: Sep 11
-
Form 8-K Otis Worldwide Corp For: Sep 13
-
Form D/A White Oaks Moderate Grow
-
Form 497J Tidal Trust II
-
Form 8-K Coya Therapeutics, Inc. For: Sep 15
-
Form 8-K INTRUSION INC For: Sep 14
-
Form 424B5 Xylem Inc.
-
Form 8-K Vera Bradley, Inc. For: Sep 15
-
Form 6-K DAVION HEALTHCARE PLC For: Sep 15
-
Form 4 Lincoln International, For: Sep 15 Filed by: Weber Mary Rose
-
Form DEF 14C Marvion Inc. For: Sep 04
-
Form 4 Lincoln International, For: Sep 15 Filed by: Marvin Kristin Marie
-
Form 8-K EIDP, Inc. For: Sep 12 Filed by: Corteva, Inc.
-
Form 4 Lincoln International, For: Sep 15 Filed by: Malchow Eric Dennis
-
Form 4 Lincoln International, For: Sep 15 Filed by: Brown Robert Todd
-
Form 6-K SU Group Holdings Ltd For: Sep 15
-
Form 8-K RB GLOBAL INC. For: Sep 15
-
Form 6-K SU Group Holdings Ltd For: Sep 15
-
Form 8-K LB PHARMACEUTICALS INC For: Sep 15
-
Form D/A Stone Temple Liquid Alte
-
Form 4 Lincoln International, For: Sep 15 Filed by: Heidloff Theodore J.
-
Form 10-12B/A Vylor Inc.
-
Form 3 Opera Ltd For: Mar 18 Filed by: Jin Tian NMN
-
Form 8-K NextTrip, Inc. For: Sep 15
-
Form 4 ReNew Energy Global plc For: Sep 13 Filed by: Vaswani Kailash
-
Form 8-K ASPEN AEROGELS INC For: Sep 15
-
Form 8-K Sadot Group Inc. For: Sep 10

